Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis

Autor: Matteo Ravaioli, Gian Luca Grazi, E. Flamini, Giorgio Ercolani, Dino Amadori, Angela Riccobon, Andrea Casadei Gardini, Antonino Cavallari, Ruggero Ridolfi, Laura Ridolfi
Přispěvatelé: GARDINI A, ERCOLANI G, RICCOBON A, RAVAIOLI M, RIDOLFI L, FLAMINI E, RIDOLFI R, GRAZI G., CAVALLARI A, AMADORI D.
Rok vydání: 2004
Předmět:
Adult
Male
Interleukin 2
medicine.medical_specialty
Pathology
Colorectal cancer
medicine.medical_treatment
TIL
liver metastases
adoptive immunotherapy
colorectal cancer
Receptors
Antigen
T-Cell
chemical and pharmacologic phenomena
colorectal cancer
Immunotherapy
Adoptive
Gastroenterology
Group B
NO
Lymphocytes
Tumor-Infiltrating
Adjuvants
Immunologic
Internal medicine
medicine
Adjuvant therapy
Hepatectomy
Humans
Prospective Studies
IMMUNOTHERAPY
Aged
business.industry
Tumor-infiltrating lymphocytes
Liver Neoplasms
T-cell receptor
Membrane Proteins
CLINICAL TRIAL
hemic and immune systems
TIL
General Medicine
Immunotherapy
Middle Aged
medicine.disease
Oncology
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
Interleukin-2
Female
Surgery
Colorectal Neoplasms
business
liver metastases
adoptive immunotherapy
Adjuvant
medicine.drug
Zdroj: Journal of Surgical Oncology. 87:46-52
ISSN: 1096-9098
0022-4790
DOI: 10.1002/jso.20066
Popis: Background and Objectives Conventional chemotherapy has not proven effective in improving long-term results of surgery for liver metastases from colorectal cancer. We assessed the usefulness of immunotherapy with tumor infiltrating lymphocytes (TIL) plus Interleukin-2 (IL-2) as adjuvant treatment. Methods Between 1995 and 1998, 47 patients were enrolled onto a prospective protocol; 25 entered the treatment group (A) and 22 entered the control group (B). All patients had undergone radical liver resection. TIL obtained from surgical specimens from group A patients were cultured and activated in vitro with IL-2, then reinfused into the patients with IL-2. We investigated pre- and post-IL-2 stimulation expression of T cell receptor (TCR) ζ- and e-chains, p56lck, Fas, and Fas-L by TIL immunostaining. Results Fourteen patients from group A (56%) received immunotherapy; 14 from group B (60%) underwent conventional chemotherapy, and the remaining 19 patients did not receive any treatment. No significant differences between the two groups were found in the actuarial and disease-free survival (DSF) rates after 1, 3, and 5 years. After IL-2 exposure, TCR ζ-chain expression significantly increased (P = 0.001); An increase in TCR e-chain expression (P = 0.04), and p56lck (P = 0.03) was detected; TCR e-chain expression was significantly increased in disease-free patients compared to those who relapsed (P = 0.04). Fas-L expression was correlated with the TCR e-chain and p56lck levels (P = 0.05). Conclusions Our data suggest that we are still a long way from being able to propose TIL + IL-2 treatment as an effective adjuvant therapy. However, the results confirm that the biological indicators examined could play an important role in modulating immunitary response against tumor cells. J. Surg. Oncol. 2004;87:46–52. © 2004 Wiley-Liss, Inc.
Databáze: OpenAIRE
Externí odkaz: